{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T14:08:47Z","timestamp":1771423727502,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15533-7","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T05:35:16Z","timestamp":1767764116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective analysis of high-dose-rate brachytherapy for patients with prostate cancer aged\u2009\u2265\u200975 years"],"prefix":"10.1186","volume":"26","author":[{"given":"Keiji","family":"Matsuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Kamitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoji","family":"Tokiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Miyaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Komura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Tamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Katsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"15533_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"15533_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390396","volume":"43","author":"LS Graham","year":"2023","unstructured":"Graham LS, Lin JK, Lage DE, Kessler ER, Parikh RB, Morgans AK. Management of prostate cancer in older adults. Am Soc Clin Oncol Educ Book. 2023;43:e390396. https:\/\/doi.org\/10.1200\/EDBK_390396.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"15533_CR3","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","volume":"69","author":"DA Siegel","year":"2020","unstructured":"Siegel DA, O\u2019Neil ME, Richards TB, Dowling NF, Weir HK. Prostate cancer incidence and survival, by stage and race\/ethnicity\u2014United States, 2001\u20132017. MMWR Morb Mortal Wkly Rep. 2020;69:1473\u201380. https:\/\/doi.org\/10.15585\/mmwr.mm6941a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"15533_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333. https:\/\/doi.org\/10.3322\/caac.21708.","journal-title":"CA Cancer J Clin"},{"key":"15533_CR5","unstructured":"National Cancer Center, National Research and Development Agency. Cancer Control Information Center: 2021 Cancer Statistics Projections . 2021 [Cited 2025 July 1]. Available from: https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/en.html"},{"key":"15533_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/jjco\/hyae030","volume":"54","author":"H Charvat","year":"2024","unstructured":"Charvat H, Okawa S. Projection of the number of new cases of prostate cancer in the world. Jpn J Clin Oncol. 2024;54:361\u20132. https:\/\/doi.org\/10.1093\/jjco\/hyae030.","journal-title":"Jpn J Clin Oncol"},{"key":"15533_CR7","first-page":"111","volume":"10","author":"A Stangelberger","year":"2008","unstructured":"Stangelberger A, Waldert M, Djavan B. Prostate cancer in elderly men. Rev Urol. 2008;10:111\u20139.","journal-title":"Rev Urol"},{"key":"15533_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14338\/IJPT-23-00002.1","volume":"10","author":"A Bao","year":"2023","unstructured":"Bao A, Barsky AR, Both S, Christodouleas JP, Deville C Jr., Tochner ZA, et al. Case-matched outcomes of proton beam and intensity-modulated radiation therapy for localized prostate cancer. Int J Part Ther. 2023;10:1\u201312. https:\/\/doi.org\/10.14338\/IJPT-23-00002.1.","journal-title":"Int J Part Ther"},{"key":"15533_CR9","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/s0360-3016(02)02829-8","volume":"53","author":"A Pollack","year":"2002","unstructured":"Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097\u2013105. https:\/\/doi.org\/10.1016\/s0360-3016(02)02829-8.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15533_CR10","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1200\/JCO.2000.18.14.2740","volume":"18","author":"R Valicenti","year":"2000","unstructured":"Valicenti R, Lu J, Pilepich M, Asbell S, Grignon D. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the radiation therapy oncology group trials. J Clin Oncol. 2000;18:2740\u20136. https:\/\/doi.org\/10.1200\/JCO.2000.18.14.2740.","journal-title":"J Clin Oncol"},{"key":"15533_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s0360-3016(98)00091-1","volume":"41","author":"MJ Zelefsky","year":"1998","unstructured":"Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491\u2013500. https:\/\/doi.org\/10.1016\/s0360-3016(98)00091-1.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15533_CR12","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.radonc.2020.09.047","volume":"154","author":"PJ Hoskin","year":"2021","unstructured":"Hoskin PJ, Rojas AM, Ostler PJ, Bryant L, Lowe GJ. Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: mature 12-year results. Radiother Oncol. 2021;154:214\u20139. https:\/\/doi.org\/10.1016\/j.radonc.2020.09.047.","journal-title":"Radiother Oncol"},{"key":"15533_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","volume":"116","author":"HJ Boyle","year":"2019","unstructured":"Boyle HJ, Alibhai S, Decoster L, Efstathiou E, Fizazi K, Mottet N, et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer. 2019;116:116\u201336. https:\/\/doi.org\/10.1016\/j.ejca.2019.04.031.","journal-title":"Eur J Cancer"},{"issue":"7","key":"15533_CR14","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/ggi.13118","volume":"17","author":"Y Ouchi","year":"2017","unstructured":"Ouchi Y, Rakugi H, Arai H, Akishita M, Ito H, Toba K, et al. <article-title update=\"added\">Redefining the elderly as aged 75\u00a0years and older: proposal from the Joint Committee of Japan Gerontological Society and the Japan Geriatrics Society. Geriatr Gerontol Int. 2017;17(7):1045\u20137. https:\/\/doi.org\/10.1111\/ggi.13118.","journal-title":"Geriatr Gerontol Int"},{"key":"15533_CR15","unstructured":"National Comprehensive Cancer Network. Prostate Cancer (version 2.2025): 2025 . 2025 [Cited 2025 July 1]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"key":"15533_CR16","unstructured":"Ministry of Health. LaW. Life expectancies at specified ages. Available from: https:\/\/www.mhlw.go.jp\/english\/database\/db-hw\/lifetb23\/dl\/lifetb23-01.pdf"},{"key":"15533_CR17","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969\u201374. https:\/\/doi.org\/10.1001\/jama.280.11.969.","journal-title":"JAMA"},{"key":"15533_CR18","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach","year":"2006","unstructured":"Roach M, Hanks G, Thames H Jr., Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965\u201374. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.04.029.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15533_CR19","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ijrobp.2003.11.035","volume":"59","author":"J Hiratsuka","year":"2004","unstructured":"Hiratsuka J, Jo Y, Yoshida K, Nagase N, Fujisawa M, Imajo Y. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:684\u201390. https:\/\/doi.org\/10.1016\/j.ijrobp.2003.11.035.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15533_CR20","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1007\/s11604-024-01621-4","volume":"42","author":"N Kamitani","year":"2024","unstructured":"Kamitani N, Watanabe K, Ikeda N, Kawata Y, Tokiya R, Hayashi T, et al. Long-term outcomes of high-dose-rate brachytherapy and external beam radiotherapy without hormone therapy for high-risk localized prostate cancer. Jpn J Radiol. 2024;42:1322\u20139. https:\/\/doi.org\/10.1007\/s11604-024-01621-4.","journal-title":"Jpn J Radiol"},{"key":"15533_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ctro.2020.09.008","volume":"25","author":"H Yamazaki","year":"2020","unstructured":"Yamazaki H, Masui K, Suzuki G, Shimizu D, Aibe N, Yamada K, et al. Radiotherapy for elder patients aged\u2009\u2265\u200980 with clinically localized prostate cancer\u2014brachytherapy enhanced late GU toxicity especially in elderly. Clin Transl Radiat Oncol. 2020;25:67\u201374. https:\/\/doi.org\/10.1016\/j.ctro.2020.09.008.","journal-title":"Clin Transl Radiat Oncol"},{"key":"15533_CR22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.brachy.2017.01.006","volume":"16","author":"H Ishiyama","year":"2017","unstructured":"Ishiyama H, Kamitani N, Kawamura H, Kato S, Aoki M, Kariya S, et al. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: an Asian Prostate HDR-BT Consortium. Brachytherapy. 2017;16:503\u201310. https:\/\/doi.org\/10.1016\/j.brachy.2017.01.006.","journal-title":"Brachytherapy"},{"key":"15533_CR23","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","volume":"82","author":"R Miralbell","year":"2012","unstructured":"Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2\u2009=\u20091.4 (0.9\u20132.2) Gy. Int J Radiat Oncol Biol Phys. 2012;82:e17\u201324. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.10.075.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15533_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7110424","volume":"7","author":"H Yamazaki","year":"2018","unstructured":"Yamazaki H, Masui K, Suzuki G, Nakamura S, Aibe N, Shimizu D, et al. Radiothrerapy for elderly patients aged\u2009\u2265\u200975 years with clinically localized prostate cancer-is there a role of brachytherapy? J Clin Med. 2018;7:424. https:\/\/doi.org\/10.3390\/jcm7110424.","journal-title":"J Clin Med"},{"key":"15533_CR25","unstructured":"EAU. EAU - EANM - ESTRO - ESUR - ISUP \u2013 SIOG Guidelines on Prostate Cancer (Limited Update. March 2025): 2025. 2025 [Cited 2025 December 1]. Available from: http:\/\/uroweb.org\/guidelines\/prostate-cancer"},{"key":"15533_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ijrobp.2009.04.085","volume":"77","author":"A Nanda","year":"2010","unstructured":"Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, et al. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2010;77:147\u201352. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.04.085.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15533_CR27","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.urology.2005.01.057","volume":"66","author":"AB Jani","year":"2005","unstructured":"Jani AB, Gratzle J. Analysis of impact of age and race on biochemical control after radiotherapy in different prostate cancer settings. Urology. 2005;66:124\u20139. https:\/\/doi.org\/10.1016\/j.urology.2005.01.057.","journal-title":"Urology"},{"key":"15533_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.radonc.2015.05.011","volume":"115","author":"NG Zaorsky","year":"2015","unstructured":"Zaorsky NG, Palmer JD, Hurwitz MD, Keith SW, Dicker AP, Den RB. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol. 2015;115:295\u2013300. https:\/\/doi.org\/10.1016\/j.radonc.2015.05.011.","journal-title":"Radiother Oncol"},{"key":"15533_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctro.2022.04.006","volume":"35","author":"D Marotte","year":"2022","unstructured":"Marotte D, Chand-Fouche ME, Boulahssass R, Hannoun-Levi JM. Irradiation of localized prostate cancer in the elderly: a systematic literature review. Clin Transl Radiat Oncol. 2022;35:1\u20138. https:\/\/doi.org\/10.1016\/j.ctro.2022.04.006.","journal-title":"Clin Transl Radiat Oncol"},{"key":"15533_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.radonc.2022.02.007","volume":"169","author":"RJM Correa","year":"2022","unstructured":"Correa RJM, Morton G, Chung HT, Tseng CL, Cheung P, Chu W, et al. Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: does dose heterogeneity matter? Radiother Oncol. 2022;169:51\u20136. https:\/\/doi.org\/10.1016\/j.radonc.2022.02.007.","journal-title":"Radiother Oncol"},{"key":"15533_CR31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.5114\/jcb.2018.81024","volume":"10","author":"TM Morgan","year":"2018","unstructured":"Morgan TM, Press RH, Cutrell PK, Zhang C, Chen Z, Rahnema S, et al. Brachytherapy for localized prostate cancer in the modern era: a comparison of patient-reported quality of life outcomes among different techniques. J Contemp Brachytherapy. 2018;10:495\u2013502. https:\/\/doi.org\/10.5114\/jcb.2018.81024.","journal-title":"J Contemp Brachytherapy"},{"key":"15533_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.radonc.2019.12.017","volume":"143","author":"H Tharmalingam","year":"2020","unstructured":"Tharmalingam H, Tsang Y, Ostler P, Wylie J, Bahl A, Lydon A, et al. Single dose high-dose rate (HDR) brachytherapy (BT) as monotherapy for localised prostate cancer: early results of a UK national cohort study. Radiother Oncol. 2020;143:95\u2013100. https:\/\/doi.org\/10.1016\/j.radonc.2019.12.017.","journal-title":"Radiother Oncol"},{"key":"15533_CR33","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.radonc.2021.02.028","volume":"158","author":"YM Tsang","year":"2021","unstructured":"Tsang YM, Tharmalingam H, Belessiotis-Richards K, Armstrong S, Ostler P, Hughes R, et al. Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: high-dose-rate brachytherapy vs stereotactic ablative radiotherapy. Radiother Oncol. 2021;158:184\u201390. https:\/\/doi.org\/10.1016\/j.radonc.2021.02.028.","journal-title":"Radiother Oncol"},{"key":"15533_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2004.10.014","volume":"74","author":"L Astr\u00f6m","year":"2005","unstructured":"Astr\u00f6m L, Pedersen D, Mercke C, Holm\u00e4ng S, Johansson KA. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol. 2005;74:157\u201361. https:\/\/doi.org\/10.1016\/j.radonc.2004.10.014.","journal-title":"Radiother Oncol"},{"key":"15533_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/s0360-3016(02)02733-5","volume":"53","author":"AA Martinez","year":"2002","unstructured":"Martinez AA, Gustafson G, Gonzalez J, Armour E, Mitchell C, Edmundson G, et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:316\u201327. https:\/\/doi.org\/10.1016\/s0360-3016(02)02733-5.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15533_CR36","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0360-3016(98)00097-2","volume":"41","author":"TP Mate","year":"1998","unstructured":"Mate TP, Gottesman JE, Hatton J, Gribble M, Van Hollebeke L. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys. 1998;41:525\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15533_CR37","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.clon.2004.12.005","volume":"17","author":"GC Morton","year":"2005","unstructured":"Morton GC. The emerging role of high-dose-rate brachytherapy for prostate cancer. Clin Oncol (R Coll Radiol). 2005;17:219\u201327. https:\/\/doi.org\/10.1016\/j.clon.2004.12.005.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"15533_CR38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"WJ Morris","year":"2017","unstructured":"Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98:275\u201385. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.11.026.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15533_CR39","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.eururo.2004.11.014","volume":"47","author":"S Deger","year":"2005","unstructured":"Deger S, Boehmer D, Roigas J, Schink T, Wernecke KD, Wiegel T, et al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol. 2005;47:441\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2004.11.014.","journal-title":"Eur Urol"},{"key":"15533_CR40","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.radonc.2008.11.013","volume":"91","author":"L Sullivan","year":"2009","unstructured":"Sullivan L, Williams SG, Tai KH, Foroudi F, Cleeve L, Duchesne GM. Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiother Oncol. 2009;91:232\u20136. https:\/\/doi.org\/10.1016\/j.radonc.2008.11.013.","journal-title":"Radiother Oncol"},{"key":"15533_CR41","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.eururo.2014.08.009","volume":"68","author":"BF Koontz","year":"2015","unstructured":"Koontz BF, Bossi A, Cozzarini C, Wiegel T, D\u2019Amico A. A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol. 2015;68:683\u201391. https:\/\/doi.org\/10.1016\/j.eururo.2014.08.009.","journal-title":"Eur Urol"},{"key":"15533_CR42","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.urology.2019.05.034","volume":"131","author":"SE Martin","year":"2019","unstructured":"Martin SE, Begun EM, Samir E, Azaiza MT, Allegro S, Abdelhady M. Incidence and morbidity of radiation-induced hemorrhagic cystitis in prostate cancer. Urology. 2019;131:190\u20135. https:\/\/doi.org\/10.1016\/j.urology.2019.05.034.","journal-title":"Urology"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15533-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15533-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15533-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T13:26:52Z","timestamp":1771421212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15533-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15533"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15533-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"16 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments and was approved by the Ethics Committee of Kawasaki Medical School (approval number: 5329-03). The need for informed consent was exempted owing to the retrospective nature of the study. The choice to opt out was provided through notifications displayed on the institutional\u2019s website.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"273"}}